Science Explorer Back to mapMap
Discussion
Topic · Epidemiology

Neuroendocrine Tumor Research Advances

Neuroendocrine Tumor Research Advances is a research topic within Epidemiology. Science Explorer counts 44k research works in it since 1950. 10.1% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the epidemiology, classification, management, and treatment of neuroendocrine tumors, with a specific emphasis on pancreatic neuroendocrine tumors. It covers topics such as somatostatin receptor-based imaging and therapy, MEN1 syndrome, peptide receptor radionuclide therapy, genetic mutations associated with these tumors, and survival analysis.

  • Neuroendocrine Tumors
  • Pancreatic Neuroendocrine Tumors
  • Somatostatin Receptor
  • MEN1 Syndrome
  • Peptide Receptor Radionuclide Therapy
  • Gastroenteropancreatic Neoplasms
  • Tumor Classification
  • Survival Analysis
  • Therapeutic Guidelines
  • Genetic Mutations
Research works
44k
fractional, since 1950
In the world top 10%
4.4k
per year above
Top-10% rate
10.1%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+1%
the tick is no change
Largest producer
United States
32% of the 10 largest, 2022-now
Neuroendocrine Tumor Research Advances

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Neuroendocrine Tumor Research Advances research?

By volume, the United States and China publish the most (1.9k and 1.3k works in 2022-now).

By volume, 2022-now

  1. 1 United States 1.9k works
  2. 2 China 1.3k works
  3. 3 Japan 656 works
  4. 4 Italy 451 works
  5. 5 India 375 works
  6. 6 Germany 363 works
  7. 7 United Kingdom 249 works
  8. 8 France 243 works
  9. 9 Spain 223 works
  10. 10 South Korea 174 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 32.3%China: 21.3%Japan: 11.1%Italy: 7.6%6 others listed: 27.6%32%largest
United States1,907 · 32.3%China1,257 · 21.3%Japan656 · 11.1%Italy451 · 7.6%6 others listed1,627 · 27.6%

Shares of the rows listed above, not of the whole node.

Which institutions lead Neuroendocrine Tumor Research Advances research?

By volume in 2022-now, Mayo Clinic publishes the most Neuroendocrine Tumor Research Advances research, followed by Harvard University and Chinese Academy of Medical Sciences & Peking Union Medical College.

By volume, 2022-now

  1. 1 Mayo ClinicUnited States 72 works
  2. 2 Harvard UniversityUnited States 67 works
  3. 3 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 61 works
  4. 4 Sichuan UniversityChina 55 works
  5. 5 The University of Texas MD Anderson Cancer CenterUnited States 45 works
  6. 6 All India Institute of Medical SciencesIndia 44 works
  7. 7 Sun Yat-sen UniversityChina 42 works
  8. 8 National Institutes of HealthUnited States 37 works
  9. 9 Memorial Sloan Kettering Cancer CenterUnited States 34 works
  10. 10 Shanghai Jiao Tong UniversityChina 34 works

Who are the leading researchers in Neuroendocrine Tumor Research Advances?

The most-cited researchers publishing on Neuroendocrine Tumor Research Advances include Guido Kroemer, Bert Vogelstein and Gad A. Getz.

  1. 1 Guido Kroemer France 386k citations
  2. 2 Bert Vogelstein United States 373k citations
  3. 3 Gad A. Getz United States 364k citations
  4. 4 John J.V. McMurray United Kingdom 349k citations
  5. 5 Hermann Brenner Germany 343k citations
  6. 6 Jun Wang China 340k citations
  7. 7 Giuseppe Remuzzi Italy 328k citations
  8. 8 Gregory Y.H. Lip United Kingdom 311k citations
  9. 9 Richard A. Gibbs United States 292k citations
  10. 10 Matthew M. Meyerson United States 280k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Neuroendocrine Tumor Research Advances?

The most cited paper in Neuroendocrine Tumor Research Advances is "Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis" (Laurent Meijer et al., 2016), with 4,999 citations. Next come "One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States" (4,565) and "Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy" (4,339).

Most cited papers
#PaperReleasedCitations
1 Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis Laurent Meijer et al. · Journal of Innate Immunity Open access 2016 4,999
2 One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States James C. Yao, Manal M. Hassan, Alexandria T. Phan et al. · Journal of Clinical Oncology 18 Jun 2008 4,565
3 Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy Suzanne Louise Topalian, Charles G. Drake, Drew M. Pardoll · Cancer Cell Open access Apr 2015 4,339
4 Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Julie Renee Brahmer et al. · Journal of Clinical Oncology Open access 14 Feb 2018 3,766
5 Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States Arvind N. Dasari, Chan Shen, Daniel M. Halperin et al. · JAMA Oncology Open access 27 Apr 2017 3,531
All 99 most cited papers, with filters and sorting

Where is Neuroendocrine Tumor Research Advances research done?

The largest centres of Neuroendocrine Tumor Research Advances research in 2022-now are Beijing (China), Tokyo (Japan), Shanghai (China) and New York (United States).

Largest cities, 2022-now

  1. 1 BeijingChina 208 works
  2. 2 TokyoJapan 132 works
  3. 3 ShanghaiChina 118 works
  4. 4 New YorkUnited States 108 works
  5. 5 RomeItaly 95 works
  6. 6 LondonUnited Kingdom 93 works
  7. 7 SeoulSouth Korea 87 works
  8. 8 GuangzhouChina 76 works
  9. 9 ParisFrance 75 works
  10. 10 HoustonUnited States 74 works
See Neuroendocrine Tumor Research Advances on the map

Where is the best place to study Neuroendocrine Tumor Research Advances?

Among universities, judged by research, Harvard University, Chinese Academy of Medical Sciences & Peking Union Medical College and University of Naples Federico II score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 19.18%fractional works in this field (log) →share of work in the world top 10% →University of Naples…Harvard UniversityJohns Hopkins Univer…Chinese Academy of M…
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 76.922.3%3.1×67 -2.9%
2Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 64.812.4%8.5×61 +37.6%
3University of Naples Federico IIItaly 63.929.3%3.4×17 +32.6%
4Johns Hopkins UniversityUnited States 61.816.6%3.1×32 +5.1%
5Humanitas UniversityItaly 60.917.4%19.1×19 +139.1%
6Università Cattolica del Sacro CuoreItaly 60.818.8%7.4×22 +47.6%
7Erasmus University RotterdamNetherlands 60.722.7%4.6×16 -29.8%
8University of California, San FranciscoUnited States 58.020.3%4.8×23 +2.1%
9Cornell UniversityUnited States 56.422.3%2.9×26 -8.0%
10Sichuan UniversityChina 56.39.7%3.6×55 +55.4%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Neuroendocrine Tumor Research Advances, country by country

Is Neuroendocrine Tumor Research Advances research growing?

Output in 2022-2025 was 1% higher than in 2018-2021, peaking in 2021. The fastest-growing topics are Neuroendocrine Tumor Research Advances.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Neuroendocrine Tumor Research Advances as a percentage of every work published that year, 0.033% in 2024.

still counting0.025%0.050%0.075%Neuroendocrine Tumor Research Advances0.032% in 202519801990200020102020

Fractional works of Neuroendocrine Tumor Research Advances over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Neuroendocrine Tumor Research Advances10.1% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Neuroendocrine Tumor Research Advances. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.